Chimeric antigen receptor (CAR)-T cell therapy has been shown successful in a range of malignancies but due to an absence of notable antigenic targets has limited its application to acute myeloid leukaemia (AML). Here the authors identify CD84 as a potential target for AML and show that the application of CD84 CAR-T in models of AML results in reduced tumour burden and enhanced survival.
- Martina Pigazzi
- Silvia Merlini
- Alessandra Biffi
